Author(s): Yogesh Joshi

Email(s): yogeshjoshi1583@rediffmail.com

DOI: Not Available

Address: Yogesh Joshi
Assistant Professor, Department of Pharmacology, Himalayan Institute of Pharmacy & Research, Rajawala, Dehradun, Uttarakhand (India)
*Corresponding Author

Published In:   Volume - 5,      Issue - 3,     Year - 2013


ABSTRACT:
Gatifloxacin, a synthetic, novel fluoroquinolone, broad-spectrum antimicrobial agent, is primarily indicated for the treatment of upper respiratory tract infections, urinary tract infections and many more infectious disorders. It acts by inhibiting DNA gyrase and also by inhibiting topoisomerase IV for bacterial infections. Its absolute bioavailability is approximately 96%, extensively distributed into many tissues and body fluids, elimination half-life is approximately 8 hours and major route of elimination is urinary excretion of unchanged drug, with renal clearance accounting for >70%. Approximately 82-88% was recovered in urine as unchanged drug and 6% was recovered in feces. Gatifloxacin was reported to be associated with many serious glycemic abnormalities mostly observed in diabetic as well as in non-diabetic patients. Hypoglycemia usually occurs immediately after the administration while hyperglycemia often takes several days to develop and discontinuation of gatifloxacin treatment markedly improves glucose homeostasis in many cases. It was observed that dysglycemia occurs more frequently in elderly patients, patients with renal insufficiency, diabetic patients, and patients taking medications for diabetics (mainly hypoglycemic agents). One of the study identified that increased gatifloxacin exposure correlates with age-related decreases in renal function and may be responsible for elderly patients being at an increased risk for hyperglycemia. Failure to adjust the dose of gatifloxacin for renal insufficiency has been commonly associated with gatifloxacin-induced hypoglycemia and hyperglycemia. Some researchers observed high incidence rates of hyperglycemia in patients with diabetes compared to those without diabetes while some found no significant difference. Patients receiving glucose lowering medications were at the greatest risk for gatifloxacin-associated hyperglycemic events and patient’s not receiving glucose-lowering medications also had a significantly increased risk of hyperglycemia. Gatifloxacin is still being used in various parts of the world for treatment of infectious diseases. Therefore, gatifloxacin should be used with caution while undergoing treatment with gatifloxacin.


Cite this article:
Yogesh Joshi. Gatifloxacin Induced Dysglycemic Behaviour and Its Impact on Worldwide Patients. Research J. Pharmacology and Pharmacodynamics. 2013; 5(3): 187-190


Recomonded Articles:

Author(s): Shameer Pasha, Mohamed Khaleel, Sukhen Som.

DOI: Not Available         Access: Open Access Read More

Author(s): Aswani P. S., Kshirod Kumar Ratha, Dighe Dattatray Pandurang, M. M. Rao, Remya Vijayan

DOI: 10.5958/2321-5836.2018.00008.3         Access: Open Access Read More

Author(s): U. S. Jijith , C. R. Sudhakaran Nair, K. Pramod

DOI: 10.5958/2321-5836.2016.00001.X         Access: Open Access Read More

Author(s): K. Rashid, C. Senthil Kumar, P. M. Mohammed Haleel

DOI: 10.5958/2321-5836.2017.00037.4         Access: Open Access Read More

Author(s): Kadiri Sunil Kumar, S Mounica, Rajesh Behera, K Vijay Kumar, Y Shanmukh Sai, R Suthakaran

DOI: 10.5958/2321-5836.2016.00013.6         Access: Open Access Read More

Author(s): MA Halkai, Arun Patil, MD Akhil Ahmed, AK Beknal .

DOI: 10.5958/2321-5836.2016.00004.5         Access: Open Access Read More

Author(s): Suneel Kumar A, Venkatarathanamma. V, Naga Saibabu V, Nageswara Rao Tentu, Pavan Kumar Kota, K. Suneel Kumar, A. Vijayalakshmi

DOI: 10.5958/2321-5836.2017.00009.X         Access: Open Access Read More

Author(s): Rohit J. Bhor, Harshala Damdhar, Geeta Kokate, Maduri Salve, Swati Andhale

DOI: 10.5958/2321-5836.2016.00025.2         Access: Open Access Read More

Author(s): D. Benito Johnson, Faisal N.V, Rashid. K, Mohammed Haleel, V. Venkatanarayanan

DOI: 10.5958/2321-5836.2016.00018.5         Access: Open Access Read More

Author(s): Jadhav Anil G, Narkhede Sachin B, Patil Mrutyunjay B, Vidyasagar G.

DOI: Not Available         Access: Open Access Read More

Author(s): Suryawanshi CP, Patil VR, Chaudhari RY, Kale MK, Firake SD, Pimprikar RB, Patil MD, Yeshwante SB, Saindanem DS.

DOI: Not Available         Access: Open Access Read More

Author(s): Kuchake VG, Patil PH, Mahajan HS, Ingle PV, Surana SJ, Thakare MM, S Sudharshini.

DOI: Not Available         Access: Open Access Read More

Author(s): Kanase KG, Shinde NV, Bharti DK, Undale VR, Bhosale AV.

DOI: Not Available         Access: Open Access Read More

Author(s): Veeresh, Pramod Kumar, V Rama Mohan Gupta

DOI: 10.5958/2321-5836.2018.00003.4         Access: Open Access Read More

Author(s): Neeraj Vyawahare, Virendra Kagathara, Rohini Pujari, Manoj Patil, Imtiyaz Ansari and Amol Bhandare.

DOI: Not Available         Access: Open Access Read More

Author(s): Krishna Murti, Mayank Panchal, Megha Shah, Vijay Lambole.

DOI: Not Available         Access: Open Access Read More

Author(s): Naiya Devgan, Meenakshi Barsaul, Rashmi Sindhwani, Smiti Nanda , Manish Devgan.

DOI: Not Available         Access: Open Access Read More

Author(s): D Kilimozhi, V Parthasarathy , N Amuthavalli.

DOI: Not Available         Access: Open Access Read More

Research Journal of Pharmacology and Pharmacodynamics (RJPPD) is an international, peer-reviewed journal....... Read more >>>

RNI: Not Available                     
DOI: 10.5958 2321-5836 


Recent Articles




Tags